Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions
Roland R. Griffiths, William A. Richards, Robert L. Jesse, Matthew W. Johnson, Nathan D. Sepeda, Anthony P. Bossis, Stephen Ross
Psychedelic Medicine May 16, 2025 DOI: 10.1089/psymed.2023.0044 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized, parallel group, waitlist control Peer reviewed |
|---|---|
| Sample size | 29 |
| Population | Psychedelic-naïve clergy from various major world religions |
| Intervention | Psilocybin |
| Dose | 20 mg/70 kg, then 20 or 30 mg/70 kg |
| Duration | Two sessions about 1 month apart, with follow-up at 4 and 16 months after the second session |
| Topics | Psilocybin |
| Keywords | Hallucinogen Psychotherapist |
| Citations | 14 |
| Key points | Psilocybin administration in clergy was safe and produced sustained positive changes in religious attitudes, practices, and overall psychological well-being through 16 months. |
Abstract
Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy.
Methods: Participants were psychedelic-naïve clergy from various major world religions. A randomized, parallel group, waitlist control design was used to assess the effects of two supported psilocybin sessions, with participants receiving 20 and then 20 or 30 mg/70 kg about 1 month later. Outcomes were compared between the Immediate Group ( n = 13) and the Delayed Group ( n = 16) at 6 months after screening using self-report measures. The effects of psilocybin were also assessed on session days and 4 and 16 months after the second psilocybin session in the 24 participants who completed both sessions.
Results: The primary outcome assessment at 6 months after screening showed that, compared with the delayed control group, participants who had received psilocybin reported significantly greater positive changes in their religious practices, attitudes about their religion, and effectiveness as a religious leader, as well as in their non-religious attitudes, moods, and behavior. Follow-up assessments showed that positive changes in religious and non-religious attitudes and behavior were sustained through 16 months after the second psilocybin session. At that time, participants rated at least one of their psilocybin experiences to be among the top five most spiritually significant (96%), profoundly sacred (92%), psychologically insightful (83%), and psychologically meaningful (79%) of their lives. Furthermore, 42% rated one of their experiences to be the single most profound of their lifetime. At 16-months follow-up, most (79%) strongly endorsed that the experiences had positive effects on their religious practices (e.g., prayer or meditation) and their daily sense of the sacred, and most (71%) reported positive changes in their appreciation of religious traditions other than their own. Although no serious adverse events were reported, 46% rated a psilocybin experience as among the top five most psychologically challenging of their lives.
Conclusions: In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.
Comparable studies
Other randomized controlled trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... | 2006 | Double-blind study | n = 36 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
Citations in the library
Cited by 9
- How to Change Minds Ethically: Doxastic Vulnerability, Epistemic Harm Reduction, and the Role of Therapists in Psychedelic Therapy Journal of Applied Philosophy October 24, 2025
- Spiritual wellbeing in psychedelic-assisted therapy with palliative care populations: An analysis of outcome measures Palliative & Supportive Care 2026
- Psychedelic Integration and Spiritual Growth in a Christian Context Religions September 18, 2025
- Psychedelics, Harm Reduction, and Life's Big Questions: Making Sense of Spirituality and Religion After the Journey Anthropology of Consciousness August 27, 2025
- Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings. Scientific Reports July 21, 2025
and 4 more in the library
Cites 37
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 32 more in the library